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Abstract
Purpose—Venous thromboembolism (VTE) is associated with renal cell carcinoma (RCC), but
data on the effect of comorbidities are limited. Therefore, our purpose was to determine the effect
of comorbidity on VTE risk among patients with RCC.
Materials and methods—A population-based cohort of all patients with RCC (n = 8,633)
diagnosed in Denmark between 1995 and 2010 and a comparison cohort selected from the general
population and matched on age, sex, and comorbidities (n = 83,055) were identified. Risk of
subsequent VTE was estimated with 95% CI for the first 3 months, 1 year, and 5 years following
cancer diagnosis. We stratified by Charlson comorbidity index (CCI) scores to estimate excess
risk in patients with RCC vs. the comparison cohort within comorbidity strata. We also performed
subanalyses for postoperative VTE and metastases.
Results—VTE risk was higher in the RCC compared with comparison cohort, particularly during
the initial year following diagnosis (risk difference = 9.9 per 1,000 persons [95% CI: 7.7–12.2]).
After stratifying by CCI, excess risk declined with increasing comorbidities. The risk difference
was 12.3 per 1,000 persons (95% CI: 9.1–15.5) for CCI = 0 and 0.5 (95% CI: 6.0–7.0) for CCI =
4. Excess risk also declined with increasing comorbidities among patients with postoperative VTE
and among those with metastases.
Conclusions—RCC is associated with increased risk of VTE when compared with a matched
general population cohort. Risk did not appear to increase with added comorbidity burden.
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Clinical attention to VTE risk in patients with RCC is appropriate regardless of the presence or
absence of comorbidities.
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1. Introduction
Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary
embolism (PE), has been widely linked to malignancy [1–3]. A number of factors have been
implicated, including tumor-induced hypercoagulability, vascular injury from surgical
treatment, chemotherapy, radiation, and venous stasis due to immobilization [4,5]. Recently,
increased attention has been focused on other factors for VTE such as comorbidities, which
may help to identify patients at highest risk for VTE [6]. In most earlier studies, risk has
been examined in cohorts of patients with cancers at different sites [7,8]. Incidence of VTE
and associated risk factors among patients with specific cancers, such as renal cell
carcinoma (RCC), has been largely unstudied.
RCC is a common malignancy with increasing incidence [9]. Among newly diagnosed
patients with RCC who had localized disease, occurrence of VTE has been linked to
increased risk of death within 1 year of cancer diagnosis [10]. To our knowledge, no studies
have addressed VTE risk specifically in patients with RCC (outside of those focusing on
postoperative VTE). In addition, no population-based study has evaluated in detail the effect
of comorbidity and disease stage on incidence of VTE among patients with RCC. Estimating
the incidence of VTE among patients with RCC is important for better understanding the
association between this malignancy and VTE and identifying patients at highest risk.
Targeted thromboprophylaxis may be useful for patients with high-risk RCC [11], but
defining this risk category is necessary before recommending changes in clinical practice.
We assembled a large cohort of patients with RCC and a matched comparison general
population cohort using Danish registries to determine the incidence and time course of VTE
development. We hypothesized that VTE absolute risk would be higher among patients with
RCC when compared with the general population, and excess risk is highest among those
with recent surgery and more comorbidity. We therefore stratified our analyses using the
Charlson comorbidity index (CCI) score, disease stage, and history of surgery before VTE.
Ethical principles were followed according to the Declaration of Helsinki.
2. Materials and methods
2.1. Study population
We conducted a nationwide, population-based cohort study among all patients with RCC
recorded in the Danish Cancer Registry (DCR) between 1995 and 2010. In Denmark, all
medical and administrative registry records for individuals can be linked through a unique
personal registration number. We used this number to link data from the DCR, Danish
National Registry of Patients (DNRP), and the Danish Civil Registration System (CRS) [12–
14].
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We first identified individuals from the DCR with an incident RCC diagnosis (10th revision
of the International Classification of Diseases [ICD-10] code: C64) recorded between
January 1, 1995 and December 31, 2010. This period was chosen to ensure homogeneity of
VTE diagnostic procedures and RCC treatment [15]. We used the date of cancer diagnosis
specified in the DCR as the index date. Because VTE has been associated with undiagnosed
cancer, we excluded all patients with RCC (n = 232) with a VTE diagnosis before or
concurrent with the RCC index date.
2.3. Matched comparison cohort
For each patient with RCC, we used the CRS to select 10 individuals from the general
population who were alive and free of RCC on the patient’s index date, matched on year of
birth (in 5-y intervals), sex, and presence (but not exact date of diagnosis) of comorbidities
included in the CCI [16]. As in the cancer cohort, we excluded persons with VTE diagnosed
before the index date. We also excluded patients with RCC who could not be matched to
persons in the general population comparison cohort (n = 131). Members of the comparison
cohort who developed RCC were moved to the RCC cohort on the date of diagnosis and
corresponding matched comparison individuals were selected.
2.4. VTE data
The DNRP has tracked nonpsychiatric inpatient hospitalizations since 1977, with diagnoses
coded according to ICD-10 since 1993. Since 1994, outpatient hospital visits, including
essentially all specialist care in the country, have also been coded and included in the
DNRP. The RCC and general population cohorts were linked to records in the DNRP and in
the CRS, which tracks vital status and nationwide migration.
VTE was defined as the first inpatient diagnosis of PE (an embolic thrombus in the
pulmonary artery; ICD-8: 450.99; ICD-10: I26) or DVT (ICD-8: 451.00; ICD-10: I80.1–3),
excluding superficial thrombophlebitis, at any time after the index date. Only those with an
inpatient diagnosis were included, as an analysis of VTE diagnosed in outpatient clinics or
the emergency room within 5 years of the index date yielded only an additional 98 of 91,688
total cases with equal proportions noted for RCC and the comparison cohorts (0.12% and
0.11%, respectively). Patients coded as having both PE and DVT were classified as patients
with PE. Postoperative VTE, in this study, was defined as any VTE occurring in patients
who underwent any surgical procedure within 3 months (90 d) preceding the VTE event.
Patients were followed up from their RCC diagnosis/index date until occurrence of an
inpatient VTE diagnosis, death, emigration, or December 31, 2011. Members of the matched
comparison cohort were followed up from the index date until occurrence of a RCC cancer
diagnosis or for 5 years, whichever came first. Patients with RCC were also followed up for
5 years after diagnosis.
2.5. Comorbidity data
We used both inpatient and outpatient diagnoses in the DNRP to ascertain presence of
potential confounding comorbidities. The following conditions were tracked: myocardial
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infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease,
dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver
disease, diabetes types 1 and 2, hemiplegia, moderate to severe renal disease, diabetes with
end-organ damage, any tumor (except RCC), leukemia, lymphoma, moderate to severe liver
disease, metastatic solid tumors, and AIDS. Using these comorbidities, CCI scores were
computed and divided into 4 categories (0: none; 1: little; 2–3: moderate; and 4+: high)
(Refer to Table 1 for ICD-8, ICD-10 codes, and CCI calculation) [16].
2.6. Statistical analyses
We computed the distribution of persons in the RCC and comparison cohorts in categories
of demographics, and for those in the RCC cohort, the distribution of cancer characteristics.
Risk of hospitalization for VTE in the cancer and comparison cohorts was calculated using
the Kaplan-Meier statistics, with survival curves compared using log-rank tests [17]. The
associated 95% CI were calculated using the method described by Marubini and Valsecchi
[18]. Among patients with RCC, we estimated VTE risk overall and by comorbidity level,
disease stage, and time since cancer diagnosis. To compare VTE risk in patients with RCC
with that in the comparison cohort, risk differences with corresponding 95% CI were
calculated overall and for stratified analyses. Multivariable Cox proportional hazard
regression analysis was used to compute hazard ratios by taking into account the
confounding effects of age (as a continuous variable), sex (males vs. females), year of RCC
diagnosis (1995–1999 vs. 2005–2010 and 2000–2004 vs. 2005–2010), and CCI score (1 vs.
0, 2–3 vs. 0, 4+ vs. 0).
A subanalysis included the comparison stratified by cancer stage (metastatic, localized, and
nonmetastatic). To examine the role of recent surgery in VTE incidence, postoperative VTE
risks were calculated. Risk of VTE was calculated at 3 months, 1 year, and 5 years, stratified
by VTE type for RCC and the comparison cohort, treating death as a competing risk [17].
3. Results
3.1. Descriptive data
We identified 8,633 patients with the first RCC diagnosis between 1995 and 2010, after
excluding 232 patients with previous or concurrent VTE and 131 patients with no
corresponding match available, and followed them up for 19,832 person-years. We followed
up 83,055 matched members of the general population for 331,494 person-years. Overall,
62% of patients with RCC were men, and no important differences between the RCC and
comparison cohorts were noted among sex, age, and comorbidity (Table 2).
3.2. Overall VTE
Overall, risk of VTE among patients with RCC increased within the first year after
diagnosis. Subsequently, the risk increased at a rate similar to that of the matched
comparison cohort (Fig.). RCC was associated with an increased risk of any VTE diagnosis
(DVT or PE), as compared with risk in the general population cohort (Table 3). The hazard
ratio for any VTE in the first year of follow-up was 8.3 (95% CI: 6.4–10.6). The risk
difference between patients with RCC and the comparison cohort was highest for any VTE
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in the first year of follow-up: 9.9 per 1,000 persons (95% CI: 7.7–12.2). The risk difference
after 5 years of follow-up was 8.2 per 1,000 persons (95% CI: 5.1–11.3). Risk differences
did not differ substantially between 1 year and 5 years of follow-up for any VTE, DVT, or
PE cases.
3.3. Comorbidity and VTE
As the largest differences in VTE risk occurred within the first year following RCC
diagnosis, we performed a subanalysis to evaluate whether comorbidity affected VTE risks
for RCC patients during this time period. The risks across comorbidity strata were similar in
the RCC cohort while risks increased with comorbidity level within the matched comparison
cohort (Table 4). Thus, risk differences decreased with increasing comorbidity, e.g., from
12.3 per 1,000 persons (95% CI: 9.1–15.5) at 1 year for CCI score = 0 to 0.5 per 1,000
persons (95% CI: −6.0–7.0) for CCI score = 4. These decreasing point estimates reflect the
similar VTE risks in each comorbidity stratum within the RCC cohort, in contrast to
increasing VTE risk with increasing comorbidity levels within the matched comparison
cohort. Similar risk patterns were noted for DVT and PE. Broadly similar results were
observed in analyses of patients with RCC with and without metastases and their matched
comparators (data not shown). Likewise, adjusted hazard ratios also decreased as CCI scores
increased, e.g., from 14.2 (95% CI: 10.0–20.1) for CCI = 0 to 1.8 (95% CI: 0.4–8.0) for CCI
= 4 at 1 year. Regardless of the presence or absence of metastases, VTE risk was
consistently higher in all comorbidity strata of the RCC patient cohort than in the matched
comparison cohort.
3.4. Comorbidity and postoperative VTE
The RCC patient cohort had an elevated risk of postoperative VTE at 3 months, 1 year, and
5 years, both overall and in all comorbidity strata when compared with the matched general
population cohort (Table 5). The risk differences decreased with increasing comorbidity,
e.g., from 6.6 per 1,000 persons (95% CI: 4.3–8.9) at 1 year for CCI score = 0 to 0.9 per
1,000 persons (95% CI: −3.6 to 5.4) for CCI score = 4. The adjusted hazard ratios also
decreased with increasing comorbidity, with a hazard ratio at 1 year of 35.9 (95% CI: 18.2–
71.0) for CCI score = 0 and 2.7 (95% CI: 0.3–24.7) for CCI score = 4.
4. Discussion
In a large population-based cohort study, we found convincing evidence that patients with
RCC have a greater risk of VTE than a comparison population matched on age, gender, and
comorbidity, most markedly during the year following RCC diagnosis. When evaluating
those who have had surgery in the prior 3 months or metastasis, VTE risk was found to be
even higher. Interestingly, our results also demonstrated that VTE risk decreases with
increasing comorbidity indices, when compared with that of the population cohort.
Our study extends the literature regarding comorbidity and VTE incidence. Its results
disprove the hypothesis that comorbidity increases risk of VTE in RCC. Patients in the
lowest comorbidity category had higher hazard ratios than patients in higher comorbidity
categories. The combination of a rising VTE risk with increasing comorbidity among
Smith et al. Page 5






















persons in the comparison cohort and decreased risk among patients in the RCC cohort
suggests a consistently elevated risk of VTE among all comorbidity strata of patients with
RCC.
As in earlier studies [19], we found that surgery within 3 months of VTE conferred a
significant increased risk of any VTE. However, the pattern noted for comorbidity status
remained consistent in this setting as well, with a stable risk of VTE with increasing
comorbidity burden. Furthermore, this pattern held among patients with both metastatic and
nonmetastatic disease, suggesting that this finding is not driven by stage alone.
As with all studies that rely on registry data, limitations include lack of data on subjects’
personal and clinical characteristics. Furthermore, our findings may be affected by
unmeasured confounders such as obesity, aggressive tumor histology, and functional status,
which may increase the observed effect of cancer on VTE risk. In addition, the effect of
RCC treatment may also affect this risk. Finally, temporal changes in the diagnostic workup
for VTE occurring during the study period may have influenced our results. However, an
analysis of computed tomography scan and ultrasound utilization revealed that 65% of those
in the RCC cohort were diagnosed with VTE using imaging as compared with 71% in the
comparison cohort. Thus, our results should estimate VTE risk conservatively, as slightly
less imaging use may have underestimated the incidence of VTE diagnosed in the RCC
cohort. Another consideration involves incidental diagnosis of VTE through imaging of
patients with RCC; however, given that VTE diagnosis through imaging was similar in both
cohorts, the likelihood that this is a significant bias is low. It must also be noted that a
proportion of patients with VTE may be managed as outpatients, and this may differ
between those with RCC and the general population. As another possible source of variation
between cohorts, upper extremity VTE can occur as a complication of indwelling catheters
used in patients with cancer during chemotherapy treatment. RCC is not often treated with
traditional systemic chemotherapy however, so it is unlikely that many patients in our study
received this treatment.
Despite these limitations, the study advances our understanding of the relation between VTE
incidence and RCC, as well as the association of VTE with comorbidity. An increased risk
of VTE was noted for patients with RCC in comparison to the matched general population
cohort during 3 months following diagnosis and persisted during 1 to 5 years of follow-up.
However, VTE risks among patients with RCC did not vary within strata of CCI scores.
Thus, clinical attention to VTE risk should be paid to patients with RCC regardless of the
presence or absence of comorbidities, as all patients are at substantially higher risk than the
general population, particularly in the year after their cancer diagnosis. This finding may
translate to other cancer sites, and further investigation is warranted to clarify whether
comorbidity status (an often-used basis for risk stratification) is a predictor of VTE risk
among patients with other cancers.
5. Conclusions
In a population-based cohort of patients with RCC diagnosed in Denmark and a matched
comparison population cohort, VTE risk remained constant and elevated among those with
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RCC throughout all comorbidity strata. This finding persisted with stratification by prior
surgery as well as the presence or absence of metastases. Comorbidity status may not be a
useful risk stratification tool for patients with RCC when determining VTE risk.
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Table 1
Charlson comorbidity index with ICD-8 and ICD-10 codes
Diseases ICD-8 ICD-10 Score
1 Myocardial infarction 410 I21; I22; I23 1
2 Congestive heart failure 427.09; 427.10; 427.11; 427.19; 428.99;
782.49
I50; I11.0; I13.0; I13.2 1
3 Peripheral vascular disease 440; 441; 442; 443; 444; 445 I70; I71; I72; I73; I74; I77 1
4 Cerebrovascular disease 430–438 I60–I69; G45; G46 1
5 Dementia 290.09–290.19; 293.09 F00–F03; F05.1; G30 1
6 Chronic pulmonary disease 490–493; 515–518 J40–J47; J60–J67; J68.4; J70.1; J70.3;
J84.1; J92.0; J96.1; J98.2; J98.3
1
7 Connective tissue disease 712; 716; 734; 446; 135.99 M05; M06; M08; M09; M30; M31; M32;
M33; M34; M35; M36; D86
1
8 Ulcer disease 530.91; 530.98; 531–534 K22.1; K25–K28 1
9 Mild liver disease 571; 573.01; 573.04 B18; K70.0–K70.3; K70.9; K71; K73; K74;
K76.0
1
10 Diabetes type 1
Diabetes type 2
249.00; 249.06; 249.07; 249.09





11 Hemiplegia 344 G81; G82 2
12 Moderate to severe renal disease 403; 404; 580–583; 584; 590.09; 593.19;
753.10–753.19; 792
I12; I13; N00–N05; N07; N11; N14; N17–
N19; Q61
2








14 Any tumor (except RCC) 140–194 (excluding 189.0x) C00–C75 (excluding C64) 2
15 Leukemia 204–207 C91–C95 2
16 Lymphoma 200–203; 275.59 C81–C85; C88; C90; C96
17 Moderate to severe liver disease 070.00; 070.02; 070.04; 070.06; 070.08;
573.00; 456.00–456.09
B15.0; B16.0; B16.2; B19.0; K70.4; K72;
K76.6; I85
3
18 Metastatic solid tumor 195–198; 199 C76–C80 6
19 AIDS 079.83 B21–B24 6
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Table 2
Characteristics of RCC patient cohort and matched comparison cohort, Denmark, 1995 to 2010
Characteristic RCC cohort (n = 8,633) Matched comparison cohorta (n = 83,055)
Total number Percentage (%) Total number Percentage (%)
Sex
 Female 3,284 38.0 31,653 38.1
 Male 5,349 62.0 51,402 61.9
Age at diagnosis/index date, y
 ≤59 2,554 29.6 25,415 30.5
 60–69 2,488 28.8 23,967 28.9
 70–79 2,417 28.0 22,586 27.2
 80+ 1,174 13.6 11,087 13.3
Year of cancer diagnosis
 1995–1999 2,401 27.8 23,132 27.9
 2000–2004 2,566 29.7 24,834 29.9
 2005–2010 3,666 42.5 35,089 42.2
Cancer stage
 Nonmetastatic 4,732 54.8 – –
 Metastatic 2,597 30.1 – –
 Unknown 1,304 15.1 – –
Comorbidity
 Myocardial infarction 528 6.1 4,684 5.6
 Congestive heart failure 448 5.2 3,703 4.5
 Peripheral vascular disease 414 4.8 3,498 4.2
 Cerebrovascular disease 723 8.4 6,576 7.9
 Dementia 58 0.7 474 0.6
 Chronic obstructive pulmonary disease 686 7.9 6,192 7.5
 CTD 217 2.5 1,919 2.3
 Ulcer disease 446 5.2 3,888 4.7
 Mild liver disease 85 1.0 746 0.9
 Hemiplegia 13 0.2 115 0.1
 Moderate to severe renal disease 265 3.1 2,068 2.5
 Diabetes type 1 or 2 531 6.2 4,653 5.6
 Diabetes with end-organ damage 221 2.6 1,776 2.1
 Any tumor (except RCC) 930 10.8 8,539 10.3
 Leukemia 22 0.3 155 0.2
 Lymphoma 50 0.6 382 0.5
 Moderate to severe liver disease 33 0.4 266 0.3
 Metastatic solid tumor (except RCC) 132 1.5 1,048 1.3
 AIDS 3 0.0 20 0.0
Charlson comorbidity index score
 0 4,980 57.7 49,170 59.2
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Characteristic RCC cohort (n = 8,633) Matched comparison cohorta (n = 83,055)
Total number Percentage (%) Total number Percentage (%)
 1 1,532 17.7 14,924 18.0
 2–3 1,667 19.3 15,871 19.1
 4+ 454 5.3 3,090 3.7
CTD = connective tissue disease.
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Table 3














 Any VTE 7.1 (5.5, 9.0) 0.5 (0.4–0.7) 6.6 (4.8, 8.3) 16.0 (10.8, 23.8)
 DVT 2.9 (1.9, 4.2) 0.3 (0.2, 0.4) 2.6 (1.5, 3.8) 12.2 (6.9, 21.6)
 PE 4.2 (3.0, 5.7) 0.2 (0.1, 0.4) 3.9 (2.6, 5.3) 20.4 (11.7, 35.6)
1 y
 Any VTE 11.8 (9.7, 14.3) 1.9 (1.6, 2.2) 9.9 (7.7, 12.2) 8.3 (6.4, 10.6)
 DVT 5.4 (4.1, 7.2) 1.1 (0.9, 1.3) 4.4 (2.8, 5.9) 6.6 (4.6, 9.4)
 PE 6.4 (4.9, 8.2) 0.8 (0.6, 1.0) 5.6 (3.9, 7.3) 10.5 (7.3, 15.0)
5 y
 Any VTE 18.7 (15.9, 21.9) 10.5 (9.8, 11.3) 8.2 (5.1, 11.3) 3.5 (2.9, 4.1)
 DVT 9.3 (7.4, 11.6) 5.5 (5.0, 6.1) 3.8 (1.6, 6.0) 3.2 (2.5, 4.2)
 PE 9.4 (7.5, 11.7) 5.0 (4.5, 5.5) 4.4 (2.2, 6.6) 3.7 (2.9, 4.7)
a
Risk per 1,000 persons over 3 mo, 1 y, or 5 y of follow-up.
b
Matched on year of birth (in 5-y intervals), sex, and presence of comorbidities.
c
Adjusted for age, sex, year of RCC diagnosis, and comorbidities.
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Table 4
Risks of VTE, PE, and DVT by CCI score among persons in the RCC and matched comparison cohorts in the
initial year following diagnosis date/index date
Charlson comorbidity










 0 13.5 (10.5, 17.0) 1.2 (0.9, 1.5) 12.3 (9.1, 15.5) 14.2 (10.0, 20.1)
 1 9.8 (5.8, 15.8) 2.3 (1.6, 3.2) 7.5 (2.5, 12.5) 6.1 (3.3, 11.2)
 2–3 10.8 (6.7, 16.7) 3.2 (2.4, 4.2) 7.6 (2.5, 12.6) 4.6 (2.7, 7.9)
 4 4.4 (0.9, 14.9) 3.9 (2.1, 6.7) 0.5 (−6.0, 7.0) 1.8 (0.4, 8.0)
DVT
 0 6.2 (4.3, 8.7) 0.8 (0.6, 1.1) 5.5 (3.3, 7.7) 10.2 (6.3, 16.4)
 1 5.2 (2.5, 10.0) 1.6 (1.1, 2.4) 3.6 (−0.1, 7.3) 4.6 (2.0, 10.2)
 2–3 3.6 (1.5, 7.6) 1.3 (0.9, 2.0) 2.3 (−0.7, 5.2) 3.5 (1.4, 8.7)
 4 4.4 (0.9, 14.9) 2.3 (1.0, 4.6) 2.1 (−4.2, 8.5) 3.5 (0.7, 17.0)
PE
 0 7.2 (5.2, 9.9) 0.4 (0.3, 0.6) 6.8 (4.5, 9.2) 21.4 (12.4, 37.1)
 1 4.6 (2.1, 9.1) 0.7 (0.4, 1.2) 3.9 (0.5, 7.3) 9.8 (3.7, 25.9)
 2–3 7.2 (4.0, 12.3) 1.9 (1.3, 2.7) 5.3 (1.2, 9.4) 5.4 (2.8, 10.6)
 4 – 1.6 (0.6, 3.7) – –
a
Risk per 1,000 persons during 1 y of follow-up.
b
Matched on year of birth (in 5-y intervals), sex, and presence of comorbidities.
c
Adjusted for age, sex, and year of RCC diagnosis.
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